cyclotherapeutics
  • Purpose
    • Overview
  • Team
    • Leadership Team
  • Patients and Families
    • Our Commitment
    • Patient Resources
    • Patient Events
    • Newsletters
    • Letter to the NPC Community
    • Ongoing Clinical Trials
      • TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C
      • Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease
    • Expanded Access Program
  • Science
    • Trappsol® Cyclo™
    • Scientific Publications
  • Pipeline
    • Pipeline
    • Niemann-Pick Disease Type C
    • Alzheimer’s Disease
  • News/Events
    • News
    • Corporate Events
    • Patient Events
    • Email Alerts
  • Contact
Select Page

Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

by mpzzqmvj | Sep 7, 2022 | Press Releases

GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and...

Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

by mpzzqmvj | Aug 16, 2022 | Press Releases

– On track to commence Phase 2 study of Trappsol® Cyclo™ for the treatment of Alzheimer’s Disease before year end – Continued execution on advancement of lead development program evaluating Trappsol® Cyclo™ for Niemann-Pick...

Cyclo Therapeutics to Present at the China NPC Association Meeting

by mpzzqmvj | Aug 8, 2022 | Press Releases

GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and...

Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022

by mpzzqmvj | Jul 21, 2022 | Press Releases

GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and...

Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022

by mpzzqmvj | Jul 11, 2022 | Press Releases

GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and...
« Older Entries
Next Entries »

Cyclo Therapeutics, LLC, A Rafael Company © 2025

  • Privacy Policy
  • Disclaimer
  • Press Releases
  • Cyclo Chemicals
  • Contact
  • Follow
  • Follow
  • Follow
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of all cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT